This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://linked.opendata.cz/resource/drugbank/drug/DB04869/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB04869/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04869/identifier/pubchem-substance/
n5http://linked.opendata.cz/resource/drugbank/drug/DB04869/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04869
rdf:type
n6:Drug
n6:description
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.
n6:generalReferences
# Recober A, Russo AF: Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17665333
n6:group
investigational
n6:indication
For the treatment of migraine headaches.
owl:sameAs
n11:DB04869
dcterms:title
Olcegepant
adms:identifier
n4:2291583 n5:DB04869 n8:3025955 n9:3819966
n6:mechanismOfAction
Migraine involves dysfunction of brainstem pathways that normally modulate sensory input. The involvement of calcitonin gene-related peptide (CGRP) in migraine pathology is supported by both clinical and experimental evidence. The release of CGRP and other neuropeptides from trigeminal nerves is thought to mediate neurogeate inflammation within the meninges which contributes to the generation of severe cerebral pain experienced during migraine attack. CGRP antagonists such as olcegepant bind at CGRP receptors, blocking the effect CGRP and thus reducing inflammation.
n6:IUPAC-Name
n7:271B5B74-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B5B7A-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B5B79-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B5B76-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B5B77-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B5B78-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B5B72-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B5B70-363D-11E5-9242-09173F13E4C5 n7:271B5B73-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B5B71-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Acceptor-Count
n7:271B5B80-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B5B81-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B5B7B-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B5B7C-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B5B7E-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B5B7D-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B5B7F-363D-11E5-9242-09173F13E4C5
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
204697-65-4
n6:category
n6:Bioavailability
n7:271B5B86-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B5B88-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B5B89-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B5B85-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B5B84-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B5B87-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B5B75-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n7:271B5B82-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B5B83-363D-11E5-9242-09173F13E4C5